BLIS K12™ Reduces Throat & Ear Infections in Kindergarten Children
A new study has found BLIS K12™ to reduce the rate of throat and ear infections for children in kindergarten.
A recent study by Italy's pre-eminent researcher into probiotics has concluded that a Kiwi-developed oral probiotic, BLIS K12™, is associated with a significant reduction in ear and throat infections among children attending their first year of kindergarten.
The treated group of 111 children received a daily oral dose of BLIS K12 for six months.
During the six-month trial, the incidence of throat and ear infections was approximately 16 percent and 44 percent respectively in the treated group.
During a three-month follow-up period in a subgroup of children, the corresponding rates of infection were 15 percent and 12 percent in the treated group and 26 percent and 36 percent in the controls, suggesting a potentially prolonged benefit.
The authors reported that the results appear to demonstrate for the first time that the preventive administration of BLIS K12™ could generate positive health outcomes even in very young children who have not been pre-selected as prone to recurrent streptococcal infection or acute otitis media.
"BLIS K12™ populates the mouth and throat with a beneficial strain of Streptococcus salivarius which crowds out the bad bacteria. Think of it like a forcefield in your throat that stops the bad bacteria invading. It is effective in the prevention of Streptococcal throat infections which, if left untreated, can lead to more serious health conditions," explains BLIS Technologies chief technology officer, Dr John Hale.
Read the full article at European study shows benefits of Kiwi-developed probiotic (Scoop News, January 2017).